Klinikum der Universität München (Großhadern und Innenstadt)

Personalized augmented reality for anatomy education (2016) Ma M, Fallavollita P, Seelbach I, Von Der Heide AM, Euler E, Waschke J, Navab N Journal article Visualization of neonatal lung injury associated with mechanical ventilation using x-ray dark-field radiography (2016) Yaroshenko A, Pritzke T, Koschlig M, Kamgari N, Willer K, Gromann L, Auweter S, et al. Journal article Low-dose, phase-contrast mammography with high signal-to-noise ratio (2016) Gromann LB, Beque D, Scherer K, Willer K, Birnbacher L, Willner M, Herzen J, et al. Journal article Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016) Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al. Conference contribution The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al. Conference contribution Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial (2016) Janning M, Mueller , Vettorazzi E, Cubas-Cordova M, Gensch , Ben Batalla , Eulenburg ZC, et al. Conference contribution Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial (2016) Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hoelzle E, et al. Journal article